Juvenile Arthritis News

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights.

Patients with immune-mediated diseases have higher rates of adverse pregnancy outcomes such as preeclampsia and pre-term delivery, with lupus and systemic sclerosis conferring the largest risks, according to data published in Rheumatology.

Nearly 40% of children with oligoarticular juvenile idiopathic arthritis treated with intra-articular corticosteroids required no additional therapy, according to data published in Arthritis Research & Therapy.

The FDA has authorized the first chimeric antigen receptor T-cell clinical trial for children with systemic lupus erythematosus.

Disparities in lupus ICU admission and renal outcomes between Black and white children are greater in children’s hospitals serving more Black patients, according to data published in Arthritis Care & Research.

The FDA has approved Tyenne, the second tocilizumab biosimilar overall and the first available in both intravenous and subcutaneous formulations, according to a press release from its manufacturer.

The U.S. Department of Veterans Affairs will replace Humira with the biosimilar Hadlima on its national formulary, according to a press release from Organon, which markets biosimilar.

Apoptotic lymphocytes in peripheral blood may be a meaningful factor in the prognosis of juvenile-onset systemic lupus erythematosus, as well as a predictor of disease activity, according to data published in Pediatric Rheumatology.

A lot can change in a year. But has it?

Multidisciplinary strategies combining physical and psychological strategies were the most effective for patients with hypermobility spectrum disorders or Ehlers-Danlos syndrome, according to a systematic review.